Posted on 07/07/2010 in Pharmaceutical Company Product News AstraZeneca is to collaborate with the Medical Research Council's commercialisation company MRC Technology on a joint project into innovative new medicines.
Under the terms of the agreement, AstraZeneca and MRC Technology are to share access to each other's library of compounds, a move which will give the two organisations access to a combined total of around 150,000 agents.
These compounds are to be screened to gauge their potential efficacy against a variety of biological targets and disease areas, including cancer, neuroscience and infection, before being developed into commercial medical products.
It is hoped that the collaboration will allow the organisations to maximise the potential of their compound libraries and lead to breakthroughs that will benefit patients.
Alan Lamont, director of science and technology alliances at AstraZeneca, said: "This deal represents a novel and creative way in which we can generate more value from one of our most significant assets."
This comes after AstraZeneca recently announced that it will be providing Medicines for Malaria Venture with access to 50,000 of its compounds in an effort to discover new malaria treatments.Other news stories from 07/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
